%0 Journal Article
%T 代偿期乙肝肝硬化抗病毒治疗的研究进展<br>Advances in Antiviral Therapy for Hepatitis B Cirrhosis in the Compensated Stage
%A 张甜静
%J Advances in Clinical Medicine
%P 41-46
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.144985
%X 慢性乙型肝炎病毒(hepatitis B virus, HBV)感染是肝硬化及肝癌发生的主要病因。疾病进展与体内HBV DNA水平息息相关，抗病毒治疗能够有效抑制病毒复制，减缓肝硬化失代偿、肝细胞癌及死亡的发生，延长患者生存时间，提高患者生存质量。本文主要介绍了适合代偿期乙肝肝硬化抗病毒治疗的药物，突出各指南对代偿期乙肝肝硬化的推荐意见。<br />
Chronic hepatitis B virus (HBV) infection is the main cause of liver cirrhosis and liver cancer. Disease progression is closely related to the level of HBV DNA in the body, and antiviral therapy can effectively inhibit viral replication, slow down the occurrence of cirrhosis loss of compensation, hepatocellular carcinoma and death, prolong the survival time of the patients, and improve the quality of their survival. This article focuses on the drugs suitable for antiviral therapy for compensated hepatitis B cirrhosis, highlighting the recommendations of various guidelines for compensated hepatitis B cirrhosis.
%K 代偿期肝硬化，干扰素，抗病毒治疗<br>Compensated Cirrhosis
%K Interferon
%K Antiviral Therapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=83928